Skip to main content

TriSalus Life Sciences, Inc.

corporate_fare Company Profile

TriSalus Life Sciences, Inc.

TLSI·NASDAQ·Industrial Applications And Services·CIK 0001826667

TriSalus Life Sciences, Inc. is an oncology-focused medical technology business aiming to improve outcomes for patients with solid tumors. The company integrates its innovative delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 ("TRL9") agonist. TriSalus's technology addresses two main challenges in treating solid tumors: high intratumoral pressure, which restricts therapeutic delivery, and off-target delivery. Nelitolimod, combined with their technology, specifically targets the immunosuppressive properties of tumor immune cells in liver, pancreas, and other solid tumors. Many solid tumors, particularly desmoplastic tumors like pancreatic ductal adenocarcinoma ("PDAC"), liver tumors, and various other types, have high interstitial fluid pressure and disorganized, leaky blood vessels, which hinder therapeutic penetration and distribution. TriSalus's platform approach, Pressure-Enabled Drug Delivery ("PEDD"), modulates pressure and flow within blood vessels to enhance intravascular therapeutic delivery into tumors, aiming to increase tumor response compared to conventional delivery methods. The company's device business, including PEDD and TriNav, shows potential for growth.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for TLSI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for TLSI spans 4, 10-Q, 8-K, DEF 14A.

Recent high-impact activity:

  • CEO Mary Szela Buys 65,192 TriSalus Shares for $160,205
  • TriSalus 10-Q: Q3 Revenue $12.9M, Net Loss Narrows to $8.9M, $41.1M Cash
  • TriSalus Q3 Revenue $12.9M; 2026 Guidance Cut to $46-48M as CMS Boosts PEDD Reimbursement
  • TriSalus Q3 Revenue Up 11% but 2026 Guidance Cut to 2-6% Growth
  • FDA Clears TriSalus' TriNav Advance, Expanding PEDD Portfolio for Liver Embolization

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$45.15M
Net Income
-$39.23M
Diluted EPS
-$1.84
Op. Cash Flow
-$18.01M
Free Cash Flow
-$18.93M
Gross Profit
$38.19M
Operating Income
-$26.95M
Cash & Equivalents
$20.44M
Total Debt
$33.05M
Debt / Equity
-0.98×
Net Margin
-86.9%
Shares Outstanding
50M sh
Source: 10-K · filed 2026-03-05 · accession 0001628280-26-015163

Short Interest & Short Volume

28.45 days to cover

FINRA reported short interest of 3,312,552 shares in TLSI as of the October 30, 2026 settlement, a 3.8% decrease from the prior period — about 28.4 days to cover at its recent average daily volume. On November 20, 2026, 58.0% of TLSI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,312,552 shares as of October 30, 2026
Change vs prior period▼ 3.8%
Days to cover28.45 at avg daily volume of 116,423
Daily short volume (FINRA facilities)58.0% of 237,775 shares on November 20, 2026
5-day average short volume60.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with T →
$2.32
52-week range · as of 2026-11-19 $2.17 – $7.95
Market cap
$143.14M
Volume
539.3K (1.9× avg)
3-mo avg 286.6K
Live data · 2026-11-21 11:07 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TLSI - Latest Insights

TLSI
Nov 19, 2026, 4:40 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $2.32 info
Change: +$0.145 (+7%) info
Market Cap: $143.142M info
TLSI
Nov 10, 2026, 8:08 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.00
Real-time Price: $2.32 info
Change: -$0.6805 (-23%) info
Market Cap: $143.142M info
TLSI
Nov 10, 2026, 8:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.00
Real-time Price: $2.32 info
Change: -$0.6805 (-23%) info
Market Cap: $143.142M info
TLSI
Nov 10, 2026, 8:05 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $3.22
Real-time Price: $2.32 info
Change: -$0.900 (-28%) info
Market Cap: $143.142M info
TLSI
Sep 22, 2026, 4:15 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $4.93
Real-time Price: $2.32 info
Change: -$2.61 (-53%) info
Market Cap: $143.142M info
TLSI
May 18, 2026, 4:42 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $2.97
Real-time Price: $2.32 info
Change: -$0.650 (-22%) info
Market Cap: $143.142M info
TLSI
May 12, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.50
Real-time Price: $2.32 info
Change: -$2.18 (-48%) info
Market Cap: $143.142M info
TLSI
May 12, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.56
Real-time Price: $2.32 info
Change: -$2.24 (-49%) info
Market Cap: $143.142M info
TLSI
May 12, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.56
Real-time Price: $2.32 info
Change: -$2.24 (-49%) info
Market Cap: $143.142M info
TLSI
Apr 29, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.26
Real-time Price: $2.32 info
Change: -$1.94 (-46%) info
Market Cap: $143.142M info
TLSI
Apr 07, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.24
Real-time Price: $2.32 info
Change: -$1.92 (-45%) info
Market Cap: $143.142M info
TLSI
Mar 30, 2026, 6:17 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $3.71
Real-time Price: $2.32 info
Change: -$1.39 (-37%) info
Market Cap: $143.142M info
TLSI
Mar 05, 2026, 4:08 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $4.77
Real-time Price: $2.32 info
Change: -$2.45 (-51%) info
Market Cap: $143.142M info
TLSI
Mar 05, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.77
Real-time Price: $2.32 info
Change: -$2.45 (-51%) info
Market Cap: $143.142M info
TLSI
Mar 05, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.77
Real-time Price: $2.32 info
Change: -$2.45 (-51%) info
Market Cap: $143.142M info
TLSI
Feb 23, 2026, 4:08 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $5.16
Real-time Price: $2.32 info
Change: -$2.84 (-55%) info
Market Cap: $143.142M info
TLSI
Feb 23, 2026, 4:08 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $5.16
Real-time Price: $2.32 info
Change: -$2.84 (-55%) info
Market Cap: $143.142M info
TLSI
Feb 20, 2026, 4:30 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $5.46
Real-time Price: $2.32 info
Change: -$3.14 (-58%) info
Market Cap: $143.142M info
TLSI
Feb 20, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.46
Real-time Price: $2.32 info
Change: -$3.14 (-58%) info
Market Cap: $143.142M info
TLSI
Feb 09, 2026, 8:59 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.75
Real-time Price: $2.32 info
Change: -$2.43 (-51%) info
Market Cap: $143.142M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets